Exchange: NASDAQ·Updated 07:59 PM EDT
IBRX logo

IBRXImmunityBio Inc

$9.44
$0.24
(2.61%)
Today
Closed $9.44
$0.04
(0.42%)
After Hours
Mkt Cap$9.64B
Vol14.67M
News
all
press releases
IBRX Stock At 3-Month High: Retail Bulls Eye July Catalysts Around Anktiva Saudi Expansion, Q2 Sales
Saudi Arabia is key to the bull case after ImmunityBio launched Anktiva there for certain patients with bladder and lung cancer.
Stocktwits
News Placeholder
More News
News Placeholder
ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?
ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
News Placeholder
SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncology
XBI, which includes both SLS and IBRX, is on track for its strongest monthly performance since December 2023.
Stocktwits
News Placeholder
IBRX Stock Surges 12% On Russell 1000 Inclusion Hopes
The semi-annual reconstitution of the index, based on market capitalizations as of April 30, 2026, will take effect after the U.S. market close on Friday, June 26.
Stocktwits
News Placeholder
Nasdaq, S&P 500 Futures Rebound As Micron Rally Lifts Chip Stocks: Why SPCX, QCOM, TSM, BABA, PLTR, CBRS, WEN, IBRX Are In Focus
Retail sentiment remained cautious, with Stocktwits data showing SPY sentiment stuck in bearish territory while QQQ sentiment improved to bullish.
Stocktwits
News Placeholder
IBRX Stock Climbs After-Hours: Retail Traders Bet Russell 1000 Inclusion Could Trigger Massive Index-Fund Buying
IBRX is already part of the Russell 2000, Russell 2500, and Russell 3000, with its current market cap around $7.67 billion.
Stocktwits
News Placeholder
Nasdaq, S&P 500 Futures Gain Ahead Of Kevin Warsh’s First Fed Meeting: Why SPCX, ASTS, INTC, MU, SOFI, SMCI Are In Focus
Stocktwits data showed retail sentiment has improved to ‘bullish’ on SPY and ‘neutral’ on QQQ from ‘bearish’ earlier in the week.
Stocktwits
News Placeholder
The Multi-Billion-Dollar Race to Defeat Glioblastoma: Why Investors Are Watching One of Oncology's Most Challenging Frontiers
Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. $NTHI, $KZIA, $BNTX, $IBRX
24-7 Market News
News Placeholder
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2, 2026, in Chicago. The presentations span two randomized...
Business Wire
News Placeholder
IBRX and the BCG Shortage: Deals That Could Expand Demand
ImmunityBio targets the BCG shortage with new supply deals and label expansion efforts that could strengthen Anktiva demand in bladder cancer.
Zacks
<
1
2
...
>

Advertisement|Remove ads.